BioGaia AB (CHIX:BIOGBS) EPS (Basic): kr3.28 (TTM As of Mar. 2026)


CHIX:BIOGBS BioGaia AB CHIX:BIOGBS
100 GF Score
Price kr120.20
GF Value kr129.06
! 4 Warning Signs
View Full Analysis

What is BioGaia AB EPS (Basic)?

BioGaia AB CHIX:BIOGBS 100 EPS (Basic) is kr3.28 as of Mar. 2026. GuruFocus rates CHIX:BIOGBS with a GF Score™ of 100/100 and a GF Value™ of kr129.06. The stock has 4 warning signs investors should review.

BioGaia AB's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was kr0.78. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was kr3.28.

BioGaia AB's EPS (Diluted) for the three months ended in Mar. 2026 was kr0.78. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was kr3.28.

BioGaia AB's EPS without NRI for the three months ended in Mar. 2026 was kr0.78. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 3.28.

During the past 12 months, BioGaia AB's average EPS without NRIGrowth Rate was 7.20% per year. During the past 3 years, the average EPS without NRI Growth Rate was 3.30% per year. During the past 5 years, the average EPS without NRI Growth Rate was 13.90% per year. During the past 10 years, the average EPS without NRI Growth Rate was 7.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, BioGaia AB's highest 3-Year average EPS without NRI Growth Rate was 135.50% per year. The lowest was -40.50% per year. And the median was 13.95% per year.

BioGaia AB  (CHIX:BIOGBs) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

BioGaia AB EPS (Basic) Related Terms

BioGaia AB EPS (Basic) Historical Data

* Premium members only.

The historical data trend for BioGaia AB's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioGaia AB EPS (Basic) Chart

BioGaia AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.94 3.70 3.62 3.48 3.29

BioGaia AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.79 0.87 0.65 0.98 0.78
CHIX:BIOGBS
100GF Score
BioGaia AB CHIX:BIOGBS
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioGaia AB EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

BioGaia AB's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(332.764-0)/101.162
=3.29

BioGaia AB's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(79.41-0)/101.162
=0.78

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr3.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of kr3.28 mean?
BioGaia AB (CHIX:BIOGBS) has a EPS (Basic) of kr3.28 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on BioGaia AB and its competitors.
Is BioGaia AB's EPS (Basic) too high?
BioGaia AB's current EPS (Basic) is kr3.28. Overall, BioGaia AB has a GF Score™ of 100/100, reflecting its overall financial health beyond just this single metric.
How does BioGaia AB's EPS (Basic) compare to ZTS?
BioGaia AB's EPS (Basic) of kr3.28 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Drug Manufacturers company?
A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on BioGaia AB and its competitors. BioGaia AB's current EPS (Basic) is kr3.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioGaia AB stock overvalued right now?
BioGaia AB (CHIX:BIOGBS) has a current EPS (Basic) of kr3.28. The stock's GF Value™ is kr129.06, compared to a current price of kr120.20 — trading 6.9% below its estimated fair value. The current EPS (Basic) is kr3.28. BioGaia AB's overall GF Score™ is 100/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For BioGaia AB (CHIX:BIOGBS), the current EPS (Basic) is kr3.28 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioGaia AB (CHIX:BIOGBS) Overvalued in 2026?

Based on GuruFocus' analysis, BioGaia AB stock appears to be undervalued. The current stock price of kr120.20 is trading 6.9% below its estimated GF Value™ of kr129.06.

Key valuation signals for CHIX:BIOGBS:

  • EPS (Basic): kr3.28
  • GF Value™: kr129.06 vs. price of kr120.20 (6.9% below fair value)
  • GF Score™: 100/100 with 4 warning signs

No single metric tells the full story. See the CHIX:BIOGBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioGaia AB Business Description

Address Kungsbroplan 3A, Stockholm, SWE, SE-112 27
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions: EMEA, the Americas, and APAC (Asia-Pacific, Australia, and New Zealand).
100GF Score

Get the complete analysis for CHIX:BIOGBS

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr120.20
Price
kr129.06
GF Value